SOURCE: IlluminOss Medical

IlluminOss Medical

December 10, 2014 10:00 ET

IlluminOss Medical Caps off Flagship Year With Addition of New Patents to Bone Fixation Portfolio

2014 Marked by Continued Success in International Orthopedics Markets and Conditional Clearance for First U.S. Clinical Trial to Begin in 2015

EAST PROVIDENCE, RI--(Marketwired - Dec 10, 2014) -  IlluminOss Medical, a commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that it has been issued two new patents related to its internal bone fixation system. IlluminOss now owns 25 issued U.S. patents and its complete intellectual property portfolio includes over 55 issued patents in 17 countries around the world -- with many more patent applications currently pending related to its revolutionary IlluminOss System for minimally invasive fixation and treatment of broken bones. 

The two U.S. patents issued on December 9th cover internal bone fixation devices and kits for repairing a weakened or fractured bone, as well as internal bone fixation devices and systems for internal fixation of a fractured bone, and methods for internal fixation of a fractured bone. The proprietary IlluminOss System incorporates the use of a thin-walled PET balloon that is infused with a liquid monomer and inserted into the intramedullary canal of the bone conforming to the shape of the patient's specific bone. The device forms as an implant once the surgeon activates the visible light delivered within the PET balloon. Once cured, the implant provides longitudinal strength and rotational stability over the length of the implant.

The addition of the new patents comes on the heels of the company receiving conditional approval from the FDA to conduct a clinical trial in the U.S. for the treatment of impending and pathologic fractures in the humerus due to metastatic carcinoma.

IlluminOss' proprietary orthopedic implant system has already been safely and effectively used in the treatment of over 700 patients to date internationally, where it has been approved for clinical applications under a CE Mark since 2010. In 2014, IlluminOss expanded its international efforts with Trimaco Ltd in Israel and Cherry Medical Solutions in Austria.

"2014 has been a pivotal year for IlluminOss, as we have continued to see successful results from the use of our orthopedic implant system in international markets and now the enrollment process is underway for our first U.S. clinical trial," said Robert Rabiner, president and CEO of IlluminOss Medical. "We are confident that our unique approach to fracture repair will be a true game changer in how orthopedic surgery will be performed around the world and we have made significant strides in the last 12 months towards furthering our place in the market and safeguarding IlluminOss' intellectual property."

IlluminOss' simple, minimally invasive procedure enables surgeons to create a patient-conforming implant. In many cases it allows the patient to get back to daily activities more quickly without the hindrance of a hard cast. Benefits observed from the use of the product in patients include smaller incisions, shorter procedure times, and more rapid post-procedure patient mobility with reduced hospital stays and lower complication rates.

Earlier this year, surgeons at St. Vinzenz-Hospital Köln in the Department for Trauma, Orthopaedics, Hand and Reconstructive Surgery headed by chief physician Prof. Dietmar Pennig were awarded the Deutsche Gesellschaft für Unfallchirurgie (DGU) Prize for Innovation 2014 for their use of IlluminOss' system for achieving significant advantages in the treatment of complex fracture situations.

IlluminOss expects to replicate the successful findings that have been achieved in Europe with its first U.S. clinical trial, and is currently enrolling sites to participate in the 2015 trial. Physicians interested in participating in this trial can contact the Clinical Affairs department for more information.

About IlluminOss

IlluminOss Medical is a privately-held, commercial stage medical device company focused on designing, developing and marketing orthopedic fracture repair products that leverage its proprietary bone stabilization technology, the IlluminOss System. This minimally invasive technology allows for fracture fixation through patient specific intramedullary implants. The system utilizes a light-curable polymer, contained within an expandable balloon catheter, to achieve bone stabilization. The revolutionary procedure is made through a small percutaneous surgical approach providing patients and clinicians with a fast, patient-specific, method of orthopedic bone stabilization. The company currently markets its products in international countries under a CE Mark for approved clinical applications through both a direct sales force and distribution networks.

Founded in 2007, IlluminOss is headquartered in East Providence, RI, and funded by Foundation Medical Partners, New Leaf Venture Partners, Tekla Capital, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital and Slater Technology. Learn more at www.illuminoss.com.

The IlluminOss products are Investigational Devices; limited by Federal law to Investigational Use and are not approved for sale in the USA.

Contact Information

  • Media Contact:
    Jordan Bouclin
    SVM Public Relations
    Email Contact
    (401)490-9700